0
Signin
countryflagCA

888-969-2592

RY 151.2 -0.6636% TD 80.12 0.9577% SHOP 83.0 1.3802% CNR 158.42 -0.9751% ENB 50.51 0.0198% CP 113.01 0.9108% BMO 119.55 0.3357% TRI 227.18 0.6334% CNQ 47.185 -0.851% BN 64.45 1.7524% ATD 82.17 -0.8208% CSU 4335.0 0.7153% BNS 62.975 -0.3402% CM 69.78 0.7508% SU 53.02 0.9136% TRP 57.81 1.1018% NGT 63.51 -3.5535% WCN 241.16 -2.9029% MFC 35.73 0.7614% BCE 45.805 0.0546%

PsyBio Therapeutics Corp

Healthcare CA PSYB

NoneCAD
-(-%)

Last update at 2024-05-09T10:20:36.478986Z

Day Range

--
LowHigh

52 Week Range

0.0050.09
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap1.28M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.52209M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -1.56250M
  • Diluted EPS TTM-0.03

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -4.88606M -11.01888M -
Minority interest - - -
Net income -4.88606M -11.01888M -
Selling general administrative 3.95M 10.28M -
Selling and marketing expenses - - -
Gross profit -0.05000M -0.06250M -
Reconciled depreciation 0.15M - -
Ebit - -9.04257M -6.43601M
Ebitda -4.71293M -10.90531M -
Depreciation and amortization - - -
Non operating income net other - - -
Operating income -4.75618M -10.90531M -
Other operating expenses - - -
Interest expense 0.02M 0.00000M 0.00000M
Tax provision - - -
Interest income - - -
Net interest income -0.02105M - -
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense - - -
Total revenue 0.00000M 0.00000M -
Total operating expenses 4.76M 10.91M -
Cost of revenue 0.05M 0.06M -
Total other income expense net -0.10883M -0.11357M -
Discontinued operations - - -
Net income from continuing ops -4.88606M -11.01888M -
Net income applicable to common shares - -11.01888M -6.43566M
Preferred stock and other adjustments - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Total assets 0.39M 4.01M -
Intangible assets - - -
Earning assets - - -
Other current assets - - -
Total liab 1.98M 1.29M -
Total stockholder equity -1.59094M 2.72M -
Deferred long term liab - - -
Other current liab - 0.60M 0.50M
Common stock - 16.97M 4.93M
Capital stock 16.88M 16.97M -
Retained earnings -21.80429M -16.91823M -5.89935M
Other liab - 0.25M -
Good will - - -
Other assets - 0.01M -
Cash 0.00085M 0.12M -
Cash and equivalents - - -
Total current liabilities 1.93M 1.04M 1.02M
Current deferred revenue - - -
Net debt - - -
Short term debt - - -
Short long term debt - - -
Short long term debt total - - -
Other stockholder equity - 2.67M 0.23M
Property plant equipment - - -
Total current assets 0.25M 4.00M 0.29M
Long term investments - - -
Net tangible assets - 2.72M -0.73691M
Short term investments 0.00000M 3.68M -
Net receivables - - -
Long term debt - - -
Inventory - - -
Accounts payable 1.33M 0.39M 0.42M
Total permanent equity - - -
Noncontrolling interest in consolidated entity - - -
Temporary equity redeemable noncontrolling interests - - -
Accumulated other comprehensive income - - -
Additional paid in capital - - -
Common stock total equity - - -
Preferred stock total equity - - -
Retained earnings total equity - - -
Treasury stock - - -
Accumulated amortization - - -
Non currrent assets other - - -
Deferred long term asset charges - - -
Non current assets total 0.14M 0.01M -
Capital lease obligations 0.14M - -
Long term debt total - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Investments 3.52M -3.73981M -3.73981M
Change to liabilities - 0.49M 0.57M
Total cashflows from investing activities - -3.56405M -3.56405M
Net borrowings - - -
Total cash from financing activities -0.05498M 10.37M 1.16M
Change to operating activities - 0.16M 0.53M
Net income -4.88606M -11.01888M -6.43566M
Change in cash 0.03M -0.14531M 0.29M
Begin period cash flow 0.12M 0.27M -
End period cash flow 0.16M 0.12M 0.27M
Total cash from operating activities -3.43703M -6.94978M -0.86376M
Issuance of capital stock 0.16M 11.28M -
Depreciation 0.15M - -
Other cashflows from investing activities - - -
Dividends paid - - -
Change to inventory - - -
Change to account receivables - 0.01M 0.01M
Sale purchase of stock -0.08810M - -
Other cashflows from financing activities - -0.90756M -0.90756M
Change to netincome - 3.40M 4.47M
Capital expenditures 0.00000M 0.00000M 0.00000M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital 0.61M 0.67M -
Stock based compensation 0.51M 2.13M -
Other non cash items 0.02M 1.19M -
Free cash flow -3.43703M -6.94978M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
PSYB
PsyBio Therapeutics Corp		 - -% - - - - 183.22 -0.5158
NGEN
NervGen Pharma Corp		 -0.05 1.71% 2.87 - - - 29.48 -6.9477
ARCH
Arch Biopartners Inc		 -0.03 1.99% 1.48 - - 37.82 - 53.05 -28.1027
MIR
MedMira Inc		 - -% 0.08 - - 170.46 - 189.94 -48.7372
TTI
Thiogenesis Therapeutics Corp.		 -0.04 5.06% 0.75 - - - 11.86 -163.0787

Reports Covered

Stock Research & News

View All

Profile

PsyBio Therapeutics Corp., a biotechnology company, engages in the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States. PsyBio Therapeutics Corp. was formerly known as Leo Acquisitions Corp. and changed its name to PsyBio Therapeutics Corp. in January 2021. The company is headquartered in Denver, Colorado.

PsyBio Therapeutics Corp

4400 West Sample Road, Coconut Creek, FL, United States, 33073

Key Executives

Name Title Year Born
Mr. Evan Mike Levine Co-Founder, CEO & Chairman 1966
Mr. Noah Isidore Davis CFO, Sec. & Director 1983
Dr. Michael Spigarelli M.B.A., M.B.E., M.D., Ph.D. Chief Scientific Officer & Chief Medical Officer 1966
Mr. Ross Carmel Chief Legal Officer & Director 1982
Mr. Andrew Jones Inventor & Chairman of Scientific Advisory Board NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.